[Form 4] enVVeno Medical Corp Insider Trading Activity

Rhea-AI Filing Summary

Francis Duhay, a director of enVVeno Medical Corp, reported the sale of 4,900 shares of the issuer's common stock on 09/15/2025 under a Rule 10b5-1 trading plan adopted in June 2025. The transactions executed during the day at prices ranging from $0.8205 to $0.84, with a reported weighted-average price of $0.83.

After the reported sale, the reporting person beneficially owned 97,444 shares as of the transaction date. The Form 4 was signed on 09/17/2025 and includes an undertaking to provide full trade details on request to regulators or security holders.

Positive

• Transaction conducted under a Rule 10b5-1 plan, indicating the sale was pre-planned and reduces concerns about opportunistic insider trading
• Full disclosure provided including weighted-average price range and undertaking to provide detailed trade data on request

Negative

• Insider sale of 4,900 shares reduces the director's direct holdings to 97,444 shares, which may attract investor attention

Insights

Financial Analyst

TL;DR: Routine insider sale executed under a pre-established 10b5-1 plan; modest reduction in holdings, likely neutral for valuation.

The reported disposal of 4,900 shares at a weighted-average price of $0.83 was completed pursuant to a Rule 10b5-1 plan adopted in June 2025, which signals the trades were pre-planned rather than opportunistic. The remaining direct beneficial ownership of 97,444 shares indicates the director retained a substantial position post-sale. Absent additional context about company-wide insider activity or material news, this single transaction alone is unlikely to materially alter investor valuation models.

Corporate Governance Expert

TL;DR: Proper disclosure and use of a 10b5-1 plan demonstrate governance compliance; sale may draw routine investor attention.

The filing clearly discloses the 10b5-1 plan and provides price range and weighted-average details, reflecting thorough disclosure practice. The director checked the Form 4 box indicating individual filing and signed the form, meeting Form 4 technical requirements. While insider sales can prompt questions, the existence of a pre-established plan reduces regulatory and insider-trading concerns. No indication of amendments or additional related-party arrangements is provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Duhay Francis

(Last) (First) (Middle)

C/O ENVVENO MEDICAL CORPORATION,

70 DOPPLER

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
enVVeno Medical Corp [ NVNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		S(1)		4,900	D	$0.83(2)	97,444	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025.

2. This transaction was executed in multiple trades during the day at prices ranging from $0.8205 to $0.84, inclusive. The weighted-average price is reported above. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were completed.

	/s/ Francis Duhay	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did enVVeno director Francis Duhay disclose on the Form 4?

He reported selling 4,900 common shares on 09/15/2025 at a weighted-average price of $0.83 under a Rule 10b5-1 trading plan.

Was the sale part of a pre-established trading plan?

Yes. The filing states the transaction was completed pursuant to a Rule 10b5-1 plan adopted in June 2025.

How many shares did Francis Duhay own after the reported sale?

97,444 shares of common stock were beneficially owned following the reported transaction.

What price range were the shares sold at?

Trades executed between $0.8205 and $0.84, with a reported weighted-average price of $0.83.

When was the Form 4 signed?

The Form 4 was signed on 09/17/2025.